The Trump administration has touted its focus on drug prices, unveiling several policy initiatives over the last year aimed at reducing costs. In 2019, it may begin narrowing its focus to Part B, according to analysts.
Every November, the Centers for Medicare & Medicaid Services (CMS) announces its Medicare physician reimbursement policies for the upcoming year. This year is no different, and physician practices have two short months to prepare for what Medicare has in store for 2019.
Once again, Pfizer is in hot water with a politician for raising prices. This time, it's Sen. Tammy Baldwin, D-Wis., who's accusing the drugmaker of playing "political games" rather than taking real action to hold down the cost of drugs.
Health and Human Services Secretary Alex Azar wants to make prescription drug pricing more transparent. We agree, but his well-intentioned plan will only confuse and mislead consumers. What's the good of listing drug prices in advertising if almost no one pays that "list price?" When patients say, "My drugs are too expensive," they're not talking
Yesterday, 339 patient, provider, and caregiver groups, on behalf of the Part B Access for Seniors and Physicians Coalition (ASP Coalition), sent a letter to Congress encouraging lawmakers to block the implementation of the International Pricing Index (IPI) model that was announced last month.
While the Oncology Care Model (OCM) is likely not a sustainable mode for oncology care, it will probably inform what payment structure comes next, said Michael Kolodziej, MD, vice president, chief innovation officer, ADVI Health, Inc.
The House yesterday overwhelmingly passed a bill cracking down on some of the tactics Mylan used to pay lower Medicaid rebates for the EpiPen. The Senate is hoping to pass the bill this year, Axios' Caitlin Owens reports.